Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

Date publication

septembre 2003

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno , Pr MERROUCHE Yacine , Pr PIVOT Xavier , Dr KAMINSKY Marie-Christine

Tous les auteurs :
Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/12972523

Résumé

To evaluate the efficacy and toxicity of novel chemotherapy combinations including cisplatin with gemcitabine (GC) or irinotecan (IC) for patients with carcinomas of an unknown primary site.

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Camptothecin, administration & dosage, Cisplatin, administration & dosage, Deoxycytidine, administration & dosage, Female, Humans, Male, Middle Aged, Neoplasms, Unknown Primary, drug therapy

Référence

J. Clin. Oncol.. 2003 Sep;21(18):3479-82